Malignant Giant Cell Tumor of Bone With a KRAS G12V Mutation.
| Autor: | Donigian S; Departments of Pediatrics., Whiteway SL; Pediatric Hematology and Oncology., Hipp SJ; Pediatric Hematology and Oncology., Lybeck D; Orthopedics, Brooke Army Medical Center, Fort Sam Houston, TX., Clark RO; Pediatric Hematology and Oncology. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of pediatric hematology/oncology [J Pediatr Hematol Oncol] 2022 Jan 01; Vol. 44 (1), pp. e268-e271. |
| DOI: | 10.1097/MPH.0000000000002112 |
| Abstrakt: | Malignant giant cell tumor of bone (GCTB) is a rare, aggressive, sarcoma occurring in adolescent and young adults. It is characterized by the presence of multinucleated giant cells and an aggressive clinical course. Because of the rarity of this tumor, no standard therapies have been identified. Current treatment regimens often include osteosarcoma chemotherapy protocols. We present a case of a malignant GCTB with a KRAS G12V mutation. This mutation is a known oncogenic driver that has not previously been reported on patients with malignant GCTB. Competing Interests: The authors declare no conflict of interest. (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|